Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01329991 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate
A Phase 1 study of Rheumatoid Arthritis, sponsored by Plexxikon.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 4
- Study locations
NCT01329991 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by Plexxikon. The registered enrollment target is 26 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01329991, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by Plexxikon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 4
- Study locations
Study Summary
PLX115-02 is a phase 1b study to assess how the study drug, PLX5622: 1. affects the body, 2. how the body affects PLX5622 3. the interaction of PLX5622 with Methotrexate and 4. the safety of PLX5622 in rheumatoid arthritis patients taking Methotrexate
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PLX5622
Study Locations (4)
Alabama
- Pinnacle Research Group - Anniston
Michigan
- Medical Practice of Justus Fiechtner, MD - Lansing
Pennsylvania
- Altoona Center for Clinical research - Duncansville
Texas
- Metroplex Clinical Research Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01329991
The ClinicalTrials.gov registry entry for NCT01329991 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is Plexxikon, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01329991 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Alabama, Michigan, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01329991 about?
NCT01329991 is a clinical study titled "Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate". PLX115-02 is a phase 1b study to assess how the study drug, PLX5622: 1. affects the body, 2. how the body affects PLX5622 3. the interaction of PLX5622 with Methotrexate and 4. the safety of PLX5622 in rheumatoid arthritis patients taking Methotrexate
What is the current status of trial NCT01329991?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2011-05. Estimated completion is 2011-10.
What conditions does trial NCT01329991 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT01329991?
The interventions under investigation include: Placebo (DRUG), PLX5622 (DRUG).
Who is sponsoring clinical trial NCT01329991?
This trial is sponsored by Plexxikon, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01329991 being conducted?
This trial has 4 study locations across Alabama, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
-
MAD Study of IA-14069
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RECRUITING · Phase 1
-
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.